Quantcast
Home > Quotes > CARA
CARA

Cara Therapeutics, Inc. Common Stock (CARA) Quote & Summary Data

$19.04
*  
0.28
1.49%
Get CARA Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading CARA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 19.19 / $ 18.41
Share Volume
364,895
50 Day Avg. Daily Volume
669,244
Previous Close
$ 18.76
52 Week High / Low
$ 24.30 / $ 11.46
Market Cap
751,066,253
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
364,895
50 Day Avg. Daily Volume:
669,244

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.97

Trading Range

The current last sale of $19.04 is 66.14% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 19.19 $ 24.30
 Low: $ 18.41 $ 11.46

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors. We are developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), that target the body's peripheral nervous system and certain immune cells. The U.S. Food and Drug Administration, or FDA, has conditionally accepted KORSUVA as the trade name for CR845/difelikefalin injection, an investigational drug product for the treatment of itch, whose safety and efficacy have not been fully evaluated by any regulatory authority.  ... More ...  


Risk Grade

Where does CARA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 18.75
Open Date:
Nov. 16, 2018
Close Price:
$ 18.76
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x